Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

4.04
+0.11002.80%
Post-market: 4.040.00000.00%17:01 EST
Volume:886.47K
Turnover:3.55M
Market Cap:374.39M
PE:-8.73
High:4.09
Open:3.97
Low:3.89
Close:3.93
52wk High:13.99
52wk Low:2.86
Shares:92.67M
Float Shares:83.05M
Volume Ratio:0.61
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4626
EPS(LYR):-0.5438
ROE:-33.63%
ROA:-21.56%
PB:2.96
PE(LYR):-7.43

Loading ...

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 10

Anavex Life Sciences Q1 EPS $(0.06) Beats $(0.11) Estimate

Benzinga
·
Feb 09

Anavex Life Sciences meldet im ersten Quartal (Q1) ein Forschungs- und Entwicklungsaufwand von 4,66 Mio. USD, ein Rückgang um 55 Prozent

Reuters
·
Feb 09

Anavex Life Sciences Corp: Net Loss for the Quarter of $5.7 Million, or $0.06 per Share

THOMSON REUTERS
·
Feb 09

Anavex Life Sciences Corp: Anticipates at Its Current Cash Utilization Rate, an Approximate Cash Runway of More Than 3 Years

THOMSON REUTERS
·
Feb 09

Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

GlobeNewswire
·
Feb 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 09

Anavex Life Sciences ernennt Wolfgang Liedtke zum Global Head of Neurology

Reuters
·
Feb 09

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 06

Anavex Life Sciences Corp. kündigt Bekanntgabe neuer Finanzergebnisse an

Reuters
·
Feb 03

Anavex Life Sciences on Track for Highest Close Since November 2025 -- Data Talk

Dow Jones
·
Jan 21

Anavex Joins ACCESS-AD Consortium to Advance Precision Medicine in Alzheimer’s Disease

Reuters
·
Jan 13

BRIEF-Anavex Life Sciences Appoints Senior Vice President Global Head Of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Appoints Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

Anavex Life Sciences Corp - Discussion on Potential Pathways for Nda for Alzheimer's Treatment

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp: Existing Data From Phase Iib/Iii Anavex2-73-Ad-004 Program Requested by Agency Will Be Submitted

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp - FDA Shows Interest in Anavex's Development Plans

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

GlobeNewswire
·
Jan 06

Anavex Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025